Implications of Global Pricing Policies of Pharmaceuticals for Access the Innovative Drugs: The Case of Trastuzumab in Seven Latin American Countries

Andrés Pichón-RivièreUlises Ángeles GarayFederico AugustovskiCarlos VallejosLeandro HuayanayM.D.P. NaviaA. RodríguezCharles William Cavalcante De OliveiraCicera AndradeJefferson Antonio Buendía2026-03-222026-03-22201310.1016/j.jval.2013.08.1930https://doi.org/10.1016/j.jval.2013.08.1930https://andeanlibrary.org/handle/123456789/62928enPer capitaTrastuzumabQuality-adjusted life yearActuarial scienceWillingness to payMedicineEconomicsCost effectivenessEconometricsImplications of Global Pricing Policies of Pharmaceuticals for Access the Innovative Drugs: The Case of Trastuzumab in Seven Latin American Countriesarticle